Competition & SPRQ-Nx Delay Looming — Barclays Turns Bearish on PacBio

Barclays downgrades PacBio to Underweight from Equal Weight, cuts price target to $1.50 citing competition and H1 2026 consumables slowdown ahead of SPRQ-Nx launch.